SiBone (SIBN) Competitors $18.82 +0.39 (+2.12%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SIBN vs. LIVN, WRBY, NVCR, LMAT, EYE, ENOV, CNMD, TNDM, SSII, and CDREShould you be buying SiBone stock or one of its competitors? The main competitors of SiBone include LivaNova (LIVN), Warby Parker (WRBY), NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Tandem Diabetes Care (TNDM), SS Innovations International (SSII), and Cadre (CDRE). These companies are all part of the "medical equipment" industry. SiBone vs. Its Competitors LivaNova Warby Parker NovoCure LeMaitre Vascular National Vision Enovis CONMED Tandem Diabetes Care SS Innovations International Cadre LivaNova (NASDAQ:LIVN) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership. Is LIVN or SIBN more profitable? SiBone has a net margin of -15.03% compared to LivaNova's net margin of -17.41%. LivaNova's return on equity of 13.67% beat SiBone's return on equity.Company Net Margins Return on Equity Return on Assets LivaNova-17.41% 13.67% 6.68% SiBone -15.03%-16.00%-11.69% Which has higher earnings and valuation, LIVN or SIBN? LivaNova has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLivaNova$1.25B1.96$63.23M-$4.09-11.01SiBone$167.18M4.80-$30.91M-$0.64-29.41 Which has more volatility and risk, LIVN or SIBN? LivaNova has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, SiBone has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Does the media refer more to LIVN or SIBN? In the previous week, LivaNova had 1 more articles in the media than SiBone. MarketBeat recorded 3 mentions for LivaNova and 2 mentions for SiBone. SiBone's average media sentiment score of 1.88 beat LivaNova's score of 0.92 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate LIVN or SIBN? LivaNova presently has a consensus price target of $59.29, suggesting a potential upside of 31.69%. SiBone has a consensus price target of $22.50, suggesting a potential upside of 19.55%. Given LivaNova's higher probable upside, equities analysts clearly believe LivaNova is more favorable than SiBone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LivaNova 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00SiBone 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in LIVN or SIBN? 97.6% of LivaNova shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 0.3% of LivaNova shares are held by company insiders. Comparatively, 3.9% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryLivaNova beats SiBone on 9 of the 16 factors compared between the two stocks. Get SiBone News Delivered to You Automatically Sign up to receive the latest news and ratings for SIBN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SIBN vs. The Competition Export to ExcelMetricSiBoneMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$802.11M$6.87B$5.46B$8.91BDividend YieldN/A1.04%5.36%4.15%P/E Ratio-29.4126.6326.4619.70Price / Sales4.8075.93404.54108.31Price / CashN/A21.4025.8827.49Price / Book4.734.757.925.42Net Income-$30.91M$171.62M$3.15B$248.34M7 Day Performance13.92%1.78%2.20%2.41%1 Month Performance-0.21%-0.92%4.39%4.80%1 Year Performance45.55%18.96%32.26%17.50% SiBone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SIBNSiBone4.1069 of 5 stars$18.82+2.1%$22.50+19.6%+42.5%$802.11M$167.18M-29.41350Positive NewsLIVNLivaNova2.865 of 5 stars$45.57+0.1%$59.29+30.1%-16.5%$2.48B$1.25B-11.142,900WRBYWarby Parker1.8892 of 5 stars$22.02+1.3%$22.88+3.9%+36.3%$2.27B$771.32M-183.503,780NVCRNovoCure3.7629 of 5 stars$16.61-0.5%$32.83+97.7%+5.1%$1.86B$605.22M-11.001,488News CoverageAnalyst ForecastLMATLeMaitre Vascular2.51 of 5 stars$83.38+2.0%$97.83+17.3%+0.4%$1.85B$219.86M42.11490Positive NewsEYENational Vision2.5584 of 5 stars$22.69-0.8%$18.67-17.7%+77.0%$1.81B$1.82B-68.7613,411Positive NewsENOVEnovis3.2087 of 5 stars$30.01-0.3%$58.00+93.3%-29.7%$1.72B$2.11B-2.157,367CNMDCONMED4.5783 of 5 stars$51.72-0.9%$62.20+20.3%-25.0%$1.61B$1.31B13.613,900TNDMTandem Diabetes Care4.2636 of 5 stars$20.22flat$33.43+65.3%-53.0%$1.35B$940.20M-7.272,650Positive NewsSSIISS Innovations InternationalN/A$5.65-18.4%N/AN/A$1.34B$22.13M0.004Gap DownCDRECadre3.6118 of 5 stars$32.76-0.3%$37.50+14.5%-4.5%$1.34B$567.56M34.482,284 Related Companies and Tools Related Companies LivaNova Competitors Warby Parker Competitors NovoCure Competitors LeMaitre Vascular Competitors National Vision Competitors Enovis Competitors CONMED Competitors Tandem Diabetes Care Competitors SS Innovations International Competitors Cadre Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SIBN) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SiBone Please log in to your account or sign up in order to add this asset to your watchlist. Share SiBone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
